Literature DB >> 954346

Digoxin bioavailability: formulations and rates of infusions.

F I Marcus, J Dickerson, S Pippin, M Stafford, R Bressler.   

Abstract

The bioavailability of digoxin (lanoxin) tablets, oral aqueous solution of digoxin, and capsules containing a solution of digoxin was compared with digoxin given intravenously over 1 and 3 hr. The mean peak serum concentration of digoxin after the 1-hr intravenous infusion was 5 ng/ml, after the 3-hr infusion, 3.5 ng/ml, and after the oral solution, 2.0 ng/ml. There was an equivalent bioavailability of the oral solution and reference tablets of digoxin. The digoxin in capsules tended to be better absorbed than the reference tablets. There was 21% more digoxin excreted over 6 days after the 3 hr iv infusion than after the 1 hr iv infusion. This indicates that the calculated bioavailability of an orally administered dose of digoxin may vary with the rapidity of injection of the intravenous standard. It is estimated that an oral tablet of digoxin of 0.5 mg has about the same bioavailability as 0.35 of digoxin given by slow intravenous infusion (or 0.4 mg if calculated against a rapid intravenous injection).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 954346     DOI: 10.1002/cpt1976203253

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Bioavailability assessment: methods to estimate total area (AUC O to infinity) and total amount excreted (A infinity e) and importance of blood and urine sampling scheme with application to digoxin.

Authors:  J G Wagner; J W Ayres
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

2.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

3.  Evidence of nonlinearity in digoxin pharmacokinetics.

Authors:  J G Wagner; K D Popat; S K Das; E Sakmar; H Movahhed
Journal:  J Pharmacokinet Biopharm       Date:  1981-04

4.  Drug interactions with digoxin.

Authors:  D D Brown; R Spector; R P Juhl
Journal:  Drugs       Date:  1980-09       Impact factor: 9.546

5.  Michaelis-Menten absorption kinetics in drugs: - examples and implications.

Authors:  J H Wood; K M Thakker
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

6.  A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy.

Authors:  Binfeng Xia; Tycho Heimbach; Rakesh Gollen; Charvi Nanavati; Handan He
Journal:  AAPS J       Date:  2013-07-09       Impact factor: 4.009

7.  Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.

Authors:  S M Bryson; B Whiting; J R Lawrence
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

8.  The comparative bioavailability of Lanoxin tablets and Lanoxicaps with and without sorbitol.

Authors:  J O'Grady; B F Johnson; C Bye; J French
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

9.  Bioavailability of digoxin tablets in healthy volunteers.

Authors:  C H Lee; Y J Park; C D Sands; D W Jones; J M Trang
Journal:  Arch Pharm Res       Date:  1994-04       Impact factor: 4.946

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.